Taxol Resistance Among the Different Histological Subtypes of Ovarian Cancer May Be Associated With the Expression of Class III &bgr;-Tubulin

Summary: The prognostic significance of histology has been well established in epithelial ovarian cancer (EOC). Clear cell and mucinous histologies are especially generally accepted to result in an adverse outcome because of their poor chemotherapy response. Previous reports suggested that class III &bgr;-tubulin induced taxol resistance in association with a reduced effect on microtubule dynamic instability. Thus, this study aimed to evaluate class III &bgr;-tubulin expression and examine whether the protein level of class III &bgr;-tubulin was correlated with the histological difference in chemosensitivity. Class III &bgr;-tubulin expression in EOC tissues (n = 80) was immunohistochemically scored into 4 groups (−, ±, +, ++). High-level (+, ++) class III &bgr;-tubulin expression was detected in 30 of 35 clear cell carcinomas, in 8 of 10 mucinous carcinomas, 5 of 11 endometrioid carcinomas, and 5 of 24 serous carcinomas. Nineteen patients were evaluable for response. In 5 responders, high-level class III &bgr;-tubulin expression was not detected. On the other hand, it was detected in 10 of 14 nonresponders. In some ovarian cancer cell lines, we evaluated class III &bgr;-tubulin expression by Western blot analysis. Class III &bgr;-tubulin expression in nonserous carcinoma tended to be higher than that in serous carcinoma. Taxol-resistant SKOV cells showed high-level class III &bgr;-tubulin expression compared with wild-type SKOV cells. Taxol sensitivity differing among histological subtypes in EOC is associated with the expression of class III &bgr;-tubulin.

[1]  E. Martinelli,et al.  Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients , 2006, Clinical Cancer Research.

[2]  J. Mackey,et al.  Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel , 2005, Molecular Cancer Therapeutics.

[3]  A. Frankfurter,et al.  Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. , 2005, Bulletin du cancer.

[4]  Steven J Skates,et al.  Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. , 2004, Gynecologic oncology.

[5]  Tsutomu Ohta,et al.  Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. , 2003, The American journal of pathology.

[6]  T. Rollason.  Blaustein’s Pathology of the Female Genital Tract , 2003, Springer New York.

[7]  Hailing Yang,et al.  Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. , 2003, Cell motility and the cytoskeleton.

[8]  G. Bepler,et al.  Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer , 2003, Oncogene.

[9]  T. Enomoto,et al.  Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes , 2003, Molecular and Cellular Endocrinology.

[10]  H. Kajiyama,et al.  Possible role of placental leucine aminopeptidase in the antiproliferative effect of oxytocin in human endometrial adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  V. Livolsi.  Blaustein's Pathology of the Female Genital Tract, 5th ed , 2002 .

[12]  J. Nesland,et al.  P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. , 2000, Anticancer research.

[13]  M. Kavallaris,et al.  Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol , 1999, British Journal of Cancer.

[14]  A. Gown,et al.  Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. , 1998, Gynecologic oncology.

[15]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[16]  T. Fojo,et al.  Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* , 1997, The Journal of Biological Chemistry.

[17]  W. B. Derry,et al.  Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. , 1997, Biochemistry.

[18]  M. Piver,et al.  Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum‐based chemotherapy , 1996, Cancer.

[19]  J. Berek,et al.  The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. , 1994, American journal of obstetrics and gynecology.

[20]  J. Thigpen,et al.  The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. , 1992, Gynecologic oncology.

[21]  W. Mellado,et al.  Taxol: Mechanisms of Action and Resistance a , 1986, Journal of the National Cancer Institute. Monographs.

[22]  P. Shen,et al.  Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. , 2002, Molecular cancer therapeutics.

[23]  M. Fukuoka,et al.  Mutational analysis of the beta-tubulin gene in lung cancer. , 2002, Lung cancer.

[24]  S. Silverberg.  Prognostic significance of pathologic features of ovarian carcinoma. , 1989, Current topics in pathology. Ergebnisse der Pathologie.